4.6 Review

Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis

期刊

SLEEP MEDICINE
卷 81, 期 -, 页码 268-284

出版社

ELSEVIER
DOI: 10.1016/j.sleep.2021.02.040

关键词

BMI; Diabetes; Dyslipidemia; Hypertension; Metabolic; Narcolepsy

向作者/读者索取更多资源

Narcolepsy patients show metabolic abnormalities, including higher prevalence of obesity, diabetes, hypertension, and dyslipidemia. Additionally, they have higher BMI, waist circumference, and plasma insulin levels compared to non-narcoleptic controls.
Narcolepsy, a sleep disorder characterized by loss of hypocretin neurons, has been associated with metabolic disturbances. Although the metabolic alterations in narcolepsy patients are widely investigated in the literature, the results are controversial. We performed a systematic search of literature to identify metabolic profiling studies in narcolepsy patients. A total of 48 studies were included in the meta-analysis. Narcolepsy patients exhibited higher prevalence of obesity (log OR = 0.93 [0.73-1.13], P < 0.001), diabetes mellitus (log OR = 0.64 [0.34, 0.94], P < 0.001), hypertension (log OR = 0.33 [0.11, 0.55], P < 0.001), and dyslipidemia (log OR = 1.19 [0.60, 1.77], P < 0.001) compared with non-narcoleptic controls. Narcolepsy was associated with higher BMI (SMD = 0.50 [0.32-0.68], P < 0.001), waist circumference (MD = 8.61 [2.03-15.19], P = 0.01), and plasma insulin (SMD = 0.61 [0.14-1.09], P = 0.01). Levels of fasting blood glucose (SMD = -0.25 [ -0.61,0.10], P = 0.15), BMR-RMR (SMD = -0.17 [ -0.52-0.18], P = 0.34), systolic blood pressure (SMD = 0.29 [ -0.39-0.97], P = 0.40), diastolic blood pressure (SMD = 0.39 [ -0.62, 1.40], P = 0.45), CSF melanin-concentrating hormone (MD = 5.56 [ -30.79-41.91], P = 0.76), serum growth hormone (SMD = 7.84 [ -7.90-23.57], P = 0.33), as well as plasma and CSF leptin (SMD = 0.10 [ -1.32-1.51], P = 0.89 and MD = 0.01 [ -0.02-0.04], P = 0.56, respectively) did not significantly differ between narcolepsy patients and controls. These findings necessitate early screening of metabolic alterations and cardiovascular risk factors in narcolepsy patients to reduce the morbidity and mortality rates. (C) 2021 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据